Drug class
Direct thrombin inhibitor; active moiety released from dabigatran etexilate prodrug
Mechanism of action
Directly and competitively inhibits free and clot-bound thrombin (factor IIa), preventing fibrin formation and thrombin-mediated platelet activation. In clinical products, dabigatran is delivered as the active metabolite after hydrolysis of dabigatran etexilate.
General use cases
- Prevention of stroke and systemic embolism in eligible adults with non-valvular atrial fibrillation
- Treatment of deep-vein thrombosis (DVT) and pulmonary embolism (PE) after initial parenteral anticoagulation and reduction of recurrence risk
- Prevention of venous thromboembolism following hip replacement surgery in adults; specific indications, age criteria and renal-dose restrictions are label-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
